Mixed-type liposarcoma is a rare and complex form of cancer that develops in fatty tissues. This unusual subtype contains features of more than one type of liposarcoma within the same tumor, making diagnosis and treatment planning particularly challenging. Understanding how this condition is identified and diagnosed is crucial for anyone facing this diagnosis.

Introduction: Who Should Undergo Diagnostics

If you discover a lump or mass in your body that doesn’t go away or seems to be growing, it’s important to seek medical evaluation. Mixed-type liposarcoma, like other forms of liposarcoma, often appears as a growing bump under the skin, typically in the arms, legs, or deeper tissues of the thigh. Many people don’t notice any changes in their body until the tumor becomes large enough to create visible or uncomfortable symptoms.^[1]

You should consider seeking diagnostic evaluation if you notice a persistent lump that feels firmer than normal fatty tissue, particularly if it’s located deep beneath the skin rather than just under the surface. Unlike harmless fatty tumors called lipomas, which are soft and rubbery, liposarcomas including the mixed-type variety tend to feel firmer and grow larger over time. Most liposarcomas don’t cause pain initially, but if the tumor presses against a nerve or grows large enough to affect surrounding structures, you might experience discomfort.^[4]

Early detection matters significantly because mixed-type liposarcoma can contain both less aggressive components like well-differentiated liposarcoma and more aggressive components like myxoid or round cell liposarcoma in the same tumor. The presence of multiple tissue patterns within one tumor means that treatment decisions depend heavily on accurate identification of all components present.^[3]

People between ages 40 and 65 should be especially vigilant about unusual growths, as liposarcomas most commonly affect this age group. However, certain types like myxoid liposarcoma can appear in younger individuals, sometimes between ages 35 and 55. While rare in children, when liposarcoma does occur in younger people, it typically appears during adolescence.^[1]

Diagnostic Methods

Diagnosing mixed-type liposarcoma requires multiple steps and specialized testing. The process begins with a physical examination where your doctor will evaluate the lump’s size, location, consistency, and whether it moves when touched. They’ll also check for any neurological symptoms or swollen lymph nodes that might indicate the cancer has spread.^[4]

Imaging Tests

Imaging tests are essential tools that create detailed pictures of the inside of your body, helping doctors see the tumor’s size, exact location, and relationship to nearby structures. Several different imaging techniques may be used during the diagnostic process.

Magnetic Resonance Imaging (MRI) is particularly useful for examining liposarcomas. This test uses powerful magnets and radio waves instead of radiation to create detailed images of soft tissues. MRI excels at showing the fatty nature of tumors and can reveal important details about the tumor’s boundaries and contents. For mixed-type liposarcoma, MRI can help identify different tissue components within the same tumor. The test typically shows whether the tumor is homogeneous (uniform throughout) or heterogeneous (varied in composition), which provides clues about what types of liposarcoma cells might be present.^[4]

Computed Tomography (CT) scanning uses X-rays and computer technology to create cross-sectional images of your body. CT scans are superior to MRI for showing details of bones and detecting any erosion of bone by the tumor. They can also reveal mineralization or calcium deposits within the tumor. For liposarcomas, CT scans show how much of the tumor is composed of fat versus other tissue types. Well-differentiated components typically appear as predominantly fatty masses, while other components show more varied density.^[4]

The appearance of a liposarcoma on imaging can provide important diagnostic clues. Most liposarcomas have well-defined, somewhat lobulated margins. The degree of tumor heterogeneity and how much the tumor lights up after contrast material is injected helps determine the malignancy grade. Generally, the more varied the internal structure and the more enhancement with contrast, the higher the grade of cancer.^[4]

For abdominal liposarcomas, additional imaging may include evaluation of the entire abdomen and chest to check whether the cancer has spread. Sometimes a PET scan (positron emission tomography), which shows areas of high metabolic activity that might indicate cancer, is also performed.^[10]

Biopsy Procedures

While imaging tests provide valuable information, a definitive diagnosis of mixed-type liposarcoma requires examining actual tumor tissue under a microscope. This is done through a procedure called a biopsy.^[10]

The most common biopsy method for suspected liposarcoma is a core needle biopsy, where a special needle is inserted through the skin to remove small cylinders of tissue from the tumor. This procedure is usually done with local anesthesia and image guidance (using ultrasound or CT) to ensure the needle reaches the correct location. The closed needle approach is preferred because it minimizes the risk of spreading cancer cells along the needle track.^[7]

It’s critically important that the physician performing the biopsy specializes in bone and soft tissue tumors, particularly someone trained in orthopedic oncology. The placement of the biopsy needle must be carefully planned because the biopsy tract will need to be removed during definitive surgery. Poorly planned biopsies can complicate later surgical treatment.^[7]

In some cases, particularly if the tumor location makes needle biopsy difficult or dangerous, an excisional biopsy might be performed. This means removing the entire small tumor or a larger piece during surgery for examination.^[10]

Laboratory Analysis

Once tissue samples are obtained, they’re sent to a laboratory where specialized doctors called pathologists examine them. For mixed-type liposarcoma, this analysis is particularly complex because the pathologist must identify and characterize all the different tissue types present within the tumor.^[10]

Mixed-type liposarcoma is defined by containing an irregular mixture of different liposarcoma subtypes within the same tumor. A case reported in medical literature described a tumor composed of areas of well-differentiated liposarcoma alongside areas of myxoid/round cell liposarcoma. The pathologist must carefully examine tissue samples to identify these different components and determine what proportion of each type is present.^[3]

Immunohistochemical testing involves applying special stains to tissue samples that react with specific proteins in the cells. This helps confirm the diagnosis and distinguish liposarcoma from other soft tissue tumors. Different antibodies are used to identify markers specific to fat cell tumors.^[3]

Molecular and genetic testing has become increasingly important in diagnosing liposarcomas. Different types of liposarcoma have characteristic genetic abnormalities that can be detected through advanced laboratory techniques. For mixed-type liposarcoma, molecular testing can identify the genetic signatures of each component present in the tumor.^[3]

Fluorescence in situ hybridization (FISH) is a specialized molecular technique that can detect specific genetic changes. In the reported case of mixed-type liposarcoma, FISH analysis detected amplification of the MDM2 and CDK4 genes in the well-differentiated liposarcoma areas, and translocations involving the CHOP and FUS genes in the myxoid/round cell liposarcoma areas. These genetic findings confirm the presence of both components and help explain why the tumor has mixed characteristics.^[8]

The MDM2 gene amplification is particularly significant because it’s present in over 90% of well-differentiated and dedifferentiated liposarcomas but not in other liposarcoma types. Detecting this genetic change helps confirm which component is which. Similarly, the FUS-DDIT3 (also called FUS-CHOP) translocation is found in over 95% of myxoid liposarcomas, making it a reliable marker for identifying this component.^[13]

Distinguishing Mixed-Type from Other Tumors

One important role of diagnostic testing is distinguishing mixed-type liposarcoma from other conditions. First, doctors must confirm that a fatty tumor is actually cancerous rather than a benign lipoma. Lipomas are much more common than liposarcomas and have distinctive characteristics: they’re typically soft, located just beneath the skin, smaller than 2 inches across, and don’t cause pain.^[1]

Next, if the tumor is confirmed to be liposarcoma, the specific subtype must be identified. This is particularly challenging with mixed-type liposarcoma because it contains features of multiple subtypes. The pathologist must not only recognize that different components are present but also accurately characterize each one, as this information guides treatment planning.^[3]

It’s also important for experienced pathologists to evaluate these tumors because mixed-type liposarcoma is extremely rare, and less experienced observers might misidentify the tumor or fail to recognize all components present. Having tissue samples reviewed by pathologists who specialize in soft tissue tumors can ensure accurate diagnosis.^[7]

Diagnostics for Clinical Trial Qualification

If you’re considering participating in a clinical trial for mixed-type liposarcoma treatment, additional or more specific diagnostic tests may be required. Clinical trials use standardized criteria to determine which patients can enroll, ensuring that study participants have the exact condition being studied and that results can be accurately interpreted.

Most clinical trials for liposarcoma require confirmed pathological diagnosis with detailed characterization of the tumor type. For mixed-type liposarcoma, this means documentation of which specific subtypes are present and in what proportions. Molecular testing results showing the genetic profile of the tumor are often mandatory for trial enrollment.^[13]

Imaging studies performed within a specific timeframe before enrollment are typically required. Trials often mandate that CT or MRI scans be done within 4-6 weeks of starting treatment to establish a baseline for measuring how well the treatment works. These scans must be done according to specific protocols to ensure consistency across all study sites.

For trials testing targeted therapies—treatments designed to attack specific molecular abnormalities—confirmation that your tumor carries the target is essential. For example, trials of CDK4 inhibitors require proof of CDK4 amplification in the tumor. Since mixed-type liposarcomas can contain components with different genetic profiles, the genetic testing must clearly identify which alterations are present and in which portions of the tumor.^[13]

Staging scans to determine whether cancer has spread are standard requirements for clinical trial enrollment. This typically includes CT scans of the chest, abdomen, and pelvis to look for metastatic disease. Some trials accept only patients with localized disease that hasn’t spread, while others specifically study treatments for advanced or metastatic cancer.

Blood tests measuring organ function are also standard prerequisites. Trials typically require proof that your liver, kidneys, and bone marrow are functioning adequately to handle experimental treatments. Common tests include complete blood count (measuring red cells, white cells, and platelets), comprehensive metabolic panel (evaluating liver and kidney function), and sometimes specialized tests like coagulation studies.

Performance status assessment is another important qualification criterion. This involves your doctor evaluating how well you can perform daily activities and care for yourself. Most trials use standardized scales and require that participants be able to carry out at least basic self-care activities.